Home › Companies › Akero Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Akero Therapeutics, Inc.’s Form 8-K, filed December 3, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of December 2, 2025: 2 items on Akero Therapeutics, Inc.’s Form 8-K, filed December 3, 2025: 2 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Akero Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Akero Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed December 3, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. The Merger Proposal To adopt the Agreement and Plan of Merger (as may be amended, modified or supplemented from time to time, the " Merger Agreement "), dated October 9, 2025, by and among the Company, Parent, and NN Invest Sub, Inc, a Delaware corporation | 66,887,600 | 91,361 | 50,147 | -- | 0 | 99.9% | Approved | — |
| 2. The Compensation Proposal To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by the Company to its named executive officers in connection with the Merger | 65,621,066 | 1,316,708 | 91,334 | -- | 0 | 98% | Approved | — |
Source: Akero Therapeutics, Inc., Form 8-K, filed with the SEC on December 3, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
276 asset managers disclosed a vote on at least one Akero Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Akero Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 8 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To adopt the Agreement and Plan of Merger (as may be amended, modified or supplemented from time to time, the "Merger Agreement"), dated October 9, 2025, by and among Akero Therapeutics, Inc., a Delaware corporation ("Akero"), Novo Nordisk A/S, a Danish aktieselskab ("Parent"), and NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholly owned subsidiary of Parent ("Merger Sub"), including the form of contingent value rights agreement (the "CVR Agreement") to be entered into at or immediately prior to the effective time of the Merger by a direct or indirect wholly owned subsidiary of Parent designated in the CVR Agreement, a rights agent selected by Parent and reasonably acceptable to Akero and, solely with respect to Section 6.11 of the CVR Agreement, Parent, subject to changes permitted by the Merger Agreement, pursuant to which Merger Sub will merge with and into Akero (the "Merger"), and Akero will become a direct or indirect wholly owned subsidiary of Parent.
Akero Therapeutics, Inc.’s own tally for this item (“1. The Merger Proposal To adopt the Agreement and Plan of Merger (as may be amended, modified or supplemented from time to time, the " Merger Agreement "), dated October 9, 2025, by and among the Company, Parent, and NN ”): 66,887,600 for, 91,361 against — passed, per its Form 8-K filed December 3, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1: The Merger Proposal To adopt the Agreement and Plan of Merger (as may be amended, modified or supplemented from time to time, the " Merger Agreement "), dated October 9, 2025, by and among the Company, Parent, and NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholl…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 17,308,580 for, 70,867 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,857,586 | 0 | 0 | 0 | For |
| BlackRock | 2,861,394 | 0 | 0 | 0 | For |
| State Street | 1,786,818 | 0 | 0 | 0 | For |
| Fidelity | 1,609,139 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,371,320 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 884,572 | 0 | 0 | 0 | For |
| Charles Schwab | 605,436 | 0 | 0 | 0 | For |
| American Century | 530,169 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 369,896 | 0 | 0 | 0 | For |
| Dimensional | 366,061 | 0 | 0 | 0 | For |
| Loomis Sayles | 290,788 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 256,627 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 214,300 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 213,576 | 0 | 0 | 0 | For |
| Equitable | 163,470 | 0 | 0 | 0 | For |
| TIAA | 154,717 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 145,609 | 0 | 0 | 0 | For |
| Calamos | 125,648 | 0 | 0 | 0 | For |
| GMO | 116,524 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 116,498 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 103,568 | 0 | 0 | 0 | For |
| Hartford | 102,934 | 0 | 0 | 0 | For |
| Lincoln Financial | 97,204 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 88,174 | 0 | 0 | 0 | For |
| Brighthouse | 80,097 | 0 | 0 | 0 | For |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
89% of fund votes cast · no official result
Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE ADOPTION OF THE MERGER AGREEMENT AT THE TIME OF THE SPECIAL MEETING.
The 76 asset managers below reported 15,432,744 for, 1,941,206 against, 5,496 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,857,586 | 0 | 0 | 0 | For |
| BlackRock | 2,861,394 | 0 | 0 | 0 | For |
| State Street | 6,716 | 1,780,102 | 0 | 0 | Against |
| Fidelity | 1,609,139 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,371,320 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 884,572 | 0 | 0 | 0 | For |
| Charles Schwab | 605,436 | 0 | 0 | 0 | For |
| American Century | 530,169 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 369,896 | 0 | 0 | 0 | For |
| Dimensional | 366,061 | 0 | 0 | 0 | For |
| Loomis Sayles | 290,788 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 256,627 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 214,300 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 213,576 | 0 | 0 | 0 | For |
| Equitable | 163,470 | 0 | 0 | 0 | For |
| TIAA | 154,717 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 145,609 | 0 | 0 | 0 | For |
| Calamos | 125,648 | 0 | 0 | 0 | For |
| GMO | 116,524 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 116,498 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 103,568 | 0 | 0 | 0 | For |
| Hartford | 102,934 | 0 | 0 | 0 | For |
| Lincoln Financial | 46,804 | 50,400 | 0 | 0 | Mixed |
| AIG/SunAmerica | 88,174 | 0 | 0 | 0 | For |
| Brighthouse | 80,097 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: To approve, on an advisory, non- binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.
Akero Therapeutics, Inc.’s own tally for this item (“2. The Compensation Proposal To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by the Company to its named executive officers in connection with the Mer”): 65,621,066 for, 1,316,708 against — passed, per its Form 8-K filed December 3, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The following advisory votes were cast at the Special Meeting (in person or by proxy) and the non-binding proposal was approved:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,857,580 | 5 | 0 | 0 | For |
| BlackRock | 2,861,394 | 0 | 0 | 0 | For |
| State Street | 1,784,796 | 2,022 | 0 | 0 | For |
| Fidelity | 1,609,139 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,371,320 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 884,572 | 0 | 0 | 0 | For |
| Charles Schwab | 605,436 | 0 | 0 | 0 | For |
| American Century | 529,855 | 314 | 0 | 0 | For |
| Manager Directed Portfolios | 369,896 | 0 | 0 | 0 | For |
| Dimensional | 366,061 | 0 | 0 | 0 | For |
| Loomis Sayles | 290,788 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 256,627 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 214,300 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 213,576 | 0 | 0 | 0 | For |
| Equitable | 110,050 | 53,420 | 0 | 0 | Mixed |
| TIAA | 0 | 154,717 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 0 | 0 | 145,609 | 0 | Abstain |
| Calamos | 125,648 | 0 | 0 | 0 | For |
| GMO | 116,524 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 116,498 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 103,568 | 0 | 0 | 0 | For |
| Hartford | 102,934 | 0 | 0 | 0 | For |
| Lincoln Financial | 97,204 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 88,174 | 0 | 0 | 0 | For |
| Brighthouse | 80,097 | 0 | 0 | 0 | For |
Fund voting reports, all 74 managers: 16,851,972 for, 305,354 against, 151,105 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 8,375,099 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 5,873,305 | 0 | 0 | 0 | For |
| GENERAL ATLANTIC, L.P. | 5,733,989 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,000,000 | 0 | 0 | 0 | For |
| State Street | 3,175,437 | 3,077 | 0 | 0 | For |
| GLAZER CAPITAL, LLC | 3,096,210 | 0 | 0 | 0 | For |
| BlackRock | 2,406,033 | 340 | 0 | 0 | For |
| Deep Track Capital, LP | 2,332,745 | 0 | 0 | 0 | For |
| Fidelity | 2,279,432 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,786,517 | 0 | 0 | 0 | For |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 1,318,902 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 1,125,359 | 0 | 0 | 0 | For |
| Logos Global Management LP | 1,000,000 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 763,523 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 748,741 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 745,615 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 624,526 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 619,821 | 0 | 0 | 0 | For |
| Charles Schwab | 605,490 | 0 | 0 | 0 | For |
| American Century | 584,176 | 1,178 | 0 | 0 | For |
| Gabelli | 557,738 | 0 | 0 | 0 | For |
| Loomis Sayles | 509,625 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 487,013 | 0 | 0 | 0 | For |
| Northern Trust | 2,111 | 474,117 | 0 | 0 | Against |
| ALPINE ASSOCIATES MANAGEMENT INC. | 463,831 | 0 | 0 | 0 | For |
Institutional-manager reports, all 213 managers: 56,224,528 for, 1,075,951 against, 14 abstained, 11,353 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
1% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 0 | 21,926 | 0 | 0 | Against |
Fund voting reports, all 1 managers: 21,926 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Impact Investors, Inc | 0 | 410 | 0 | 0 | Against |
| TD Waterhouse Canada Inc. | 200 | 0 | 0 | 0 | For |
| BlackRock | 76 | 0 | 0 | 0 | For |
| Coyle Financial Counsel LLC | 14 | 0 | 0 | 0 | For |
| NATURAL INVESTMENTS, LLC | 0 | 1 | 0 | 0 | Against |
Institutional-manager reports, all 5 managers: 290 for, 411 against.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Vanguard | 3,857,586 |
| 2 | BlackRock | 2,861,394 |
| 3 | State Street | 1,786,818 |
| 4 | Fidelity | 1,609,139 |
| 5 | JANUS INVESTMENT FUND | 1,371,320 |
| 6 | ACAP Strategic Fund | 884,572 |
| 7 | Charles Schwab | 605,436 |
| 8 | American Century | 530,169 |
| 9 | Manager Directed Portfolios | 369,896 |
| 10 | Dimensional | 366,061 |
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Janus Henderson | 8,375,099 |
| 2 | RTW INVESTMENTS, LP | 5,873,305 |
| 3 | GENERAL ATLANTIC, L.P. | 5,733,989 |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,000,000 |
| 5 | State Street | 3,178,514 |
| 6 | GLAZER CAPITAL, LLC | 3,096,210 |
| 7 | BlackRock | 2,406,373 |
| 8 | Deep Track Capital, LP | 2,332,745 |
| 9 | Fidelity | 2,279,432 |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,786,517 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to Akero Therapeutics, Inc. for the 2025-2026 season, so there is no denominator to divide by.
At Akero Therapeutics, Inc.'s shareholder meeting held December 2, 2025, in the 2025-2026 proxy season, 276 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 947 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory, non- binding basis, the payment of certain compensation that may be… — Akero Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Akero Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on December 3, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Akero Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Akero Therapeutics, Inc. 2025 Special Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/akero-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.